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The Gammaretroviral p12 protein has multiple
domains that function during the early stages of
replication
Darren J Wight1†, Virginie C Boucherit1†, Mirella Nader1, David J Allen1,3, Ian A Taylor2 and Kate N Bishop1*
Abstract
Background: The Moloney murine leukaemia virus (Mo-MLV) gag gene encodes three main structural proteins,
matrix, capsid and nucleocapsid and a protein called p12. In addition to its role during the late stages of infection,
p12 has an essential, but undefined, function during early post-entry events. As these stages of retroviral infection
remain poorly understood, we set out to investigate the function of p12.
Results: Examination of the infectivity of Mo-MLV virus-like particles containing a mixture of wild type and mutant
p12 revealed that the N- and C-terminal regions of p12 are sequentially acting domains, both required for p12
function, and that the N-terminal activity precedes the C-terminal activity in the viral life cycle. By creating a panel
of p12 mutants in other gammaretroviruses, we showed that these domains are conserved in this retroviral genus.
We also undertook a detailed mutational analysis of each domain, identifying residues essential for function. These
data show that different regions of the N-terminal domain are necessary for infectivity in different
gammaretroviruses, in stark contrast to the C-terminal domain where the same region is essential for all viruses.
Moreover, chimeras between the p12 proteins of Mo-MLV and gibbon ape leukaemia virus revealed that the
C-terminal domains are interchangeable whereas the N-terminal domains are not. Finally, we identified potential
functions for each domain. We observed that particles with defects in the N-terminus of p12 were unable to
abrogate restriction factors, implying that their cores were impaired. We further showed that defects in the
C-terminal domain of p12 could be overcome by introducing a chromatin binding motif into the protein.
Conclusions: Based on these data, we propose a model for p12 function where the N-terminus of p12 interacts
with, and stabilizes, the viral core, allowing the C-terminus of p12 to tether the preintegration complex to host
chromatin during mitosis, facilitating integration.
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Background
Two hallmarks of retroviral replication are reverse tran-
scription of the RNA genome into DNA and integration
of this viral cDNA into the host cell chromatin. Whilst
these enzymatic processes are well characterized, less is
known about other early replication steps, for example,
uncoating, cytoplasmic trafficking, nuclear entry and
chromatin targeting. The timing of each step and the
contribution of cellular factors in these processes are
also poorly defined [1]. Several restriction factors inhibit
various early events [2], and a better understanding of
these stages of retroviral replication would help elucidate
the mechanisms of restriction and aid the development
of novel antiviral therapies for HIV/AIDS, as well as en-
hancing the design of retroviral gene therapy vectors.
All retroviruses encode a Gag polyprotein that is
cleaved into individual proteins by the viral protease
during maturation. In addition to the three main struc-
tural proteins, matrix (MA), capsid (CA) and nucleocap-
sid (NC), most retroviral Gag proteins contain additional
cleavage products, several with unknown function(s). In
many retroviral genera, the additional protein(s) is situ-
ated between MA and CA in the Gag polyprotein [3].
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One such protein is p12 from murine leukaemia virus
(MLV). The p12 protein carries a PPPY motif known as
a late-domain (L-domain) required by all retroviruses to
recruit the cellular ESCRT machinery needed for effi-
cient viral budding [4]. Although HIV-1 does not code
for a protein between MA and CA, it does contain an L-
domain in the p6 protein located at the C-terminus of
Gag [5,6]. As well as a role during the late stages of rep-
lication, p12 has an essential, but undefined, function
during the early stages of replication [7].
It has been shown that replacing stretches of residues in
the N- and C-terminus of p12 with alanines inhibits MLV
replication before formation of the provirus [8]. Addition-
ally, these regions are intolerant to insertional mutagenesis
[9]. These p12 substitution mutant viruses exhibit two phe-
notypes with regard to the stage of arrest: 1) before/during
reverse transcription and 2) post-reverse transcription but
pre-integration of the viral cDNA [8]. Biochemical analysis
of one p12 mutant with the second phenotype (PM14)
revealed that its preintegration complex (PIC) was not bio-
chemically different from wild type virions and that the
viral cDNA is processed for integration [10]. A similar mu-
tant, p12 S61A, can also integrate in vitro [10], leading to
the hypothesis that p12 may be important for nuclear
import, nuclear retention or localization of the PIC to pre-
ferred integration sites in the host genome. LEDGF pro-
vides a chromosome tethering function for HIV-1 [11,12],
but currently no protein has been identified with such a
role for MLV.
Phosphorylation of p12 occurs during the latter stages
of infection (mainly on S61) but this modification is not
essential for early events, as viral revertants arise from
the p12 SS(61,65)AA double mutant without recovering
p12 phosphorylation [13,14]. However, Yueh and Goff
highlighted the importance of four arginine residues in
the C-terminus of p12, and suggested that the presence
of positively charged residues was required for the early
stages of replication [13]. Blocking the cleavage between
p12 and CA prevents the formation of a β-hairpin at the
N-terminus of CA and inhibits formation of the mature
viral core [15]. Whilst this is lethal to the virus, blocking
the separation of p12 from MA has only a minor effect
on infectivity [16]. Nuclear magnetic resonance studies
showed that p12 was unstructured in a fragment includ-
ing the N-terminal domain of CA [17]. In this study, no
long-range interactions between p12 and CA were
observed, although such interactions have been reported
for the p10 and CA proteins of Rous sarcoma virus in
immature particles [18]. However, a cooperative effect
between p12 and CA has been shown genetically by con-
structing chimeras between MLV and spleen necrosis
virus (SNV) [19]. Infectious virus was only formed when
the p12 protein (p18 in the case of SNV) was from
the same virus as the CA protein. Furthermore,
immunofluorescence analysis of infected cells showed
that p12 co-localized with viral DNA and CA, implying
that p12 is a functional component of the MLV PIC
[20]. This study also described the movement of p12
during infection. During interphase, p12 is present pri-
marily in the cytoplasm but during mitosis p12 is found
in the proximity of the chromosomes. Most strikingly,
p12 from a C-terminal mutant (PM14) did not display
this accumulation at chromosomes during mitosis [20],
suggesting that p12 may be involved in PIC localization.
It has recently been reported that MLV particles in-
corporate clathrin via a DLL motif within p12 [21]. The
incorporation of clathrin into HIV-1 virions through
interaction with integrase (IN) has also been reported,
although the significance of this interaction is unknown
[21,22]. However, knock down of clathrin in virus produ-
cer cells resulted in ~2 fold reduction in MLV infectivity,
whereas mutation of the DLL motif in p12 reduced in-
fectivity to <1% of wild type particles. This discrepancy
may be due to an incomplete knock down of clathrin
but it suggests that the DLL motif is important for an-
other reason. The authors concluded that the loss of in-
fectivity was due to a morphological defect in the MLV
PIC that included loss of mature p12 [21].
Here, we demonstrate that p12 contains two domains
that act in concert and can behave in a dominant nega-
tive manner. We show that these domains are conserved
in a range of gammaretroviruses, but that the N-
terminal domain is more variable and is less sensitive to
single amino acid changes than the C-terminal domain.
Nevertheless, the C-terminal domains of MLV and GaLV
are interchangeable. We also show that purified p12 is
monomeric in solution at high concentrations, eliminat-
ing oligomerisation as a mechanism for the dominant
negative effects. Importantly, we identify potential func-
tions for each domain and, based on these data, propose
a model for p12 function during the early stages of
retroviral replication.
Results
Mo-MLV vectors carrying mutations in p12 are non-
infectious but mature p12 is incorporated into particles
The p12 protein was shown to be important for early
events in replication by studies introducing mutations
into the Mo-MLV provirus [8]. In order to test the
effects of these mutations in single cycle infections in a
range of different cell lines, we cloned the same muta-
tions as Yuan et al. into a Mo-MLV Gag-Pol vector
(Figure 1A). VSV-G pseudotyped virus-like particles en-
coding LacZ were synthesized by co-transfection of
293T cells and viral titres were estimated using a modi-
fied ELISA for reverse transcriptase (RT) activity. Par-
ticle release was similar for all mutants except mutant 8
(Figure 1B). The release of mutant 8 particles was
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reduced approximately three fold. In this mutant, the
residues immediately adjacent to the L-domain required
for budding have been altered, and this may account for
the reduction in titre. In comparison, mutating the L-
domain itself reduced particle release 50–100 fold
(Figure 1B, grey bar). When equivalent RT-units of these
mutant VLPs were used to challenge canine D17 cells in
a single cycle infectivity assay, the infectivity of every
mutant was reduced 100–1000 fold compared to wild
type VLPs (Figure 1C). In addition, the infectivity of a
subset of the mutant VLPs was significantly reduced in a
panel of different cell lines (Additional file 1). Replacing
residues 46–52 with a FLAG epitope had no effect on
particle production or infectivity (Figures 1B and 1C).
These data are comparable with those seen for proviral
mutants [8] and show that the block to infection is inde-
pendent of the viral envelope and the route of entry and
that the function of p12 is not species specific.
To address whether these mutations affected proces-
sing of the Gag polyprotein, we performed immunoblot-
ting experiments with lysed viral particles. We showed
that both CA and p12 proteins were cleaved from the
Gag polyprotein in all cases (Figure 1D, top and bottom
panels respectively), implying that normal processing oc-
curred. Interestingly, our monoclonal antibody against
p12 failed to detect mutants 6 and 7 and only weakly
detected mutants 5 and 8, preferentially detecting the
mutant MA-p12 processing intermediate (Figure 1D,
middle panel). This antibody was recently used to show
that mature p12 was missing from viral particles contain-
ing mutations in the DLL motif, which is mutated in mu-
tant 8 [21]. However, using a combination of monoclonal
and polyclonal antibodies, we have shown that wild type
levels of mature p12 are, in fact, incorporated into viral
particles, although even wild type p12 is incompletely
processed (Figure 1D, middle and bottom panels and
[8,15,21]). Furthermore, our immunoblot analysis sug-
gests that the p12 monoclonal antibody epitope is found
between residues 15–30, and so poorly detects the p12
from mutant 8. Thus, none of the mutations in p12 affect
p12 processing in our experiments and equal levels of
mature p12 were found in all VLPs.
Mo-MLV vectors carrying mutations in p12 fail to
integrate their DNA
To determine the timing of the block to replication, we
performed quantitative PCR experiments to detect both
early (minus strand strong stop) and late (second strand
extension) RT products (Figure 1E, left and right panels
respectively). D17 cells were incubated with equal RT-
units of DNase-treated VLPs and grown for two weeks.
Aliquots of cells were removed at various times post in-
fection, total cellular DNA was purified and the relative
quantity of MLV DNA was measured. For wild type par-
ticles, the amount of both strong stop and second strand
products increased with time to a maximum at around 6
hours post infection and then remained at this level for
the course of the experiment (Figure 1E, red lines), im-
plying that the viral DNA had stably integrated into the
cellular genome. However, for all mutants, levels of viral
DNA initially increased, but then declined to back-
ground levels by two weeks indicating that the block to
replication was after reverse transcription but before in-
tegration. Only mutant 6 (light green line) showed
reduced accumulation of linear viral DNA compared to
wild type particles at all time points, demonstrating that
reverse transcription was impaired by this mutation.
Interestingly, in contrast to previous experiments in
NIH-3T3 cells [8], mutant 8 viral particles were fully
competent to synthesize linear viral DNA in D17 cells
(dark green line), although this DNA failed to integrate.
We observed the same phenotype in 293T cells (data not
shown). This implies that mutant 8 particles are compe-
tent to reverse transcribe in at least some cell types and
thus the timing of the block to infection for this mutant
is probably concomitant with reverse transcription.
Mixed mutant/wild type particles are infectious and
reveal two functional domains
As p12 comprises part of the Gag polyprotein, it is
incorporated into viral particles with the same frequency
as MA, CA and NC proteins. To investigate how much
p12 is actually required for function, we assessed the in-
fectivity of “mixed” viral particles that contained both
mutant and wild type p12 proteins at varying ratios
(See figure on previous page.)
Figure 1 Characterisation of p12 mutants in a Mo-MLV vector system. (A) Schematic representation of the Mo-MLV Gag-Pol expression
plasmid used in this study, showing the amino acid sequence of p12. The blocks of residues changed in each substitution mutant and the
mutant names are indicated. (B) LacZ-encoding wild type or mutant Mo-MLV virus-like particles (VLPs) were produced in 293T cells by transient
transfection and reverse transcriptase (RT) activity was quantified by a modified ELISA as a measure of virus production. Results show the mean
and range of three independent experiments. (C) Equivalent RT units of VLPs from (B) were used to challenge D17 cells. Infectivity was measured
by detection of β–galactosidase activity in a chemiluminescent reporter assay. Results are plotted as the percentage of infectivity compared to
wild type Mo-MLV and show the mean and range of three independent experiments. (D) Immunoblot analysis of VLPs from (B) showing p12
(bottom panel) and capsid (top panel) protein processing. The middle panel shows that the CRL-1890 monoclonal antibody fails to recognize
some mutant p12 proteins. (E) D17 cells were infected with wild type or mutant VLPs and total DNA was isolated at various times post infection
as indicated. The relative amounts of minus strand strong stop (left panel) or second strand extension (right panel) were measured by qPCR.
Results are representative of at least three independent experiments.
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(Figure 2A). By using the Mo-MLV p12-FLAG construct
to provide wild type p12, we confirmed that the amount
of functional p12 in total viral particles decreased as the
percentage of Mo-MLV p12-FLAG plasmid in the trans-
fection mix decreased (Figure 2B). We also demon-
strated that mixed particles were being produced by
rescuing viral infectivity of the p12 substitution mutants
by co-transfecting a Gag-Pol vector carrying an L-
domain mutation that precludes viral particle production
(Figure 2C and 2D, grey lines. Note that the absence of
points when there is a high ratio of L-domain mutant in
the transfection mix reflects the absence of virus pro-
duction). Interestingly, analysis of the infectivity of
mixed particles revealed that the phenotypes of p12
mutants fell into two groups with the exception of mu-
tant 5 (Figure 2A). Excluding mutant 5, particles that
contained p12 proteins with alterations to their N-
termini (mutants 6, 7 and 8) remained infectious as the
ratio of mutant to wild type p12 increased, until less
than ten percent of the p12 in the particle was wild type.
This implies that only a small amount of p12 is actually
required for function. Conversely, particles that con-
tained p12 proteins with alterations to their C-termini
(mutants 13, 14 and 15) lost infectivity rapidly as the
ratio of mutant to wild type p12 increased, so that parti-
cles had less than 0.5% infectivity when 50 percent of
the p12 in the transfection was wild type. This is indica-
tive of a dominant negative mutation. Particles synthe-
sized with the construct carrying mutant 5 had a third
phenotype: Infectivity correlated with the amount of
wild type p12 present in the particle until 50% of the
p12 was wild type, whereafter infectivity rapidly declined
so that when 20% of the p12 was wild type the particles
were no longer infectious.
As modifications N- and C-terminal of the L-domain
had such distinct phenotypes, and previous studies had
shown that a large region in the middle of p12 was not
sensitive to mutation [8,9], this suggested that there
were two functional domains in p12. To investigate
whether the two potential domains functioned inde-
pendently of one another, we made mixed particles with
pairs of mutant p12 constructs. We chose mutant 6 as
an N-terminal mutant (Figure 2C) and mutant 13 as a
C-terminal mutant (Figure 2D), and combined them
with every other mutant in turn. Although we could res-
cue infectivity with either FLAG-tagged wild type p12
(orange line) or p12 with an L-domain mutation (grey
line), none of the other p12 mutants could rescue the in-
fectivity of either mutant 6 or mutant 13, suggesting that
the two halves of p12 do not function independently. To
investigate which of the two main phenotypes was dom-
inant we engineered a double mutant that contained
point mutations at both the N-terminus (L16A) and the
C-terminus (R66A). Each point mutation individually
reduces particle infectivity by at least 99% (Figure 2E)
and shows the expected phenotype for an N- or C-
terminal mutant in a mixed particle assay (Figure 2E). In
the same experiment, the double mutant clearly exhib-
ited an “N-terminal phenotype”, requiring only a fraction
of the p12 to be wild type for full infectivity and display-
ing no dominant negative activity (Figure 2E, yellow
line), confirming that the N-terminus must be functional
in order to produce the dominant negative phenotype of
the C-terminal mutants.
To determine whether the spacing between the
domains was important, we deleted or inserted residues
in our Gag-Pol plasmid at positions corresponding to
the “inter-domain region” of p12 and tested the infectiv-
ity of particles made from these vectors (Figure 2F). De-
leting 11 or 21 amino acids, from residues D43-P53 and
P37-A57 respectively, or inserting either 18 or 20 extra
amino acids between residues 49 and 50 had no effect
on viral infectivity (Figure 2F), implying the two domains
do not have to be a set distance apart to function.
Similar mutations in other gammaretroviruses inhibit
infectivity
In order to examine the function of p12 in other gam-
maretroviruses, we first aligned the Gag sequences of N-
tropic MLV (N-MLV), xenotropic murine leukaemia
virus-related virus (XMRV), feline leukaemia virus
(FeLV), koala retrovirus (KoRV) and gibbon ape leukae-
mia virus (GaLV) with Mo-MLV (Figure 3A). Aligning
the p12 sequences at the PPPY motif revealed that KoRV
and GaLV had very short N-terminal regions and FeLV
had an 11 amino acid deletion in the middle of the pro-
tein. The most closely related sequences were N-MLV
and XMRV with 73% identity. Unsurprisingly, the high-
est sequence diversity between viruses was seen immedi-
ately after the PPPY motif where mutations in Mo-
MLV did not affect infectivity (Figure 1C, orange bar,
2F and [8,9,20]).
Based on these alignments, we made similar alanine
substitution mutations to Mo-MLV mutants 5–8 and
13–15 (Figure 3A, coloured boxes) in N-MLV, B-tropic
MLV (B-MLV), XMRV, FeLV and GaLV Gag-Pol plas-
mids, synthesized LacZ expressing, VSV-G pseudotyped
VLPs and tested the infectivity of these particles in D17
cells (Figure 3B-G). Of note, the sequence of B-MLV
p12 is identical to N-MLV p12 (Figure 3A); and despite
our best efforts, we were unable to clone XMRV mutant
8 (Figure 3E). As the N-terminus of GaLV was short, we
mutated TDDLL to AAAAA and named this “mutant
N” rather than mutant 5, 6 or 7 (Figure 3G). The results
of altering the C-terminal region of p12 were more read-
ily interpretable than those of the N-terminal mutants.
For all five viruses, mutants 13, 14 and 15 were more
than 100 fold less infectious than wild type viruses,
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Figure 2 Infectivity of mixed mutant/wild type p12 particles. (A) Mo-MLV LacZ-encoding VLPs containing a mixture of wild type and mutant
p12 were synthesized as described in the text. D17 cells were challenged with equal RT-units of VLPs and infectivity was determined by
measuring β–galactosidase activity. Infectivity is plotted as a percentage of the infectivity of VLPs with 100% wild type p12. (B) Mixed particles
containing various ratios of un-tagged mutant 6 p12 and FLAG-tagged wild type p12 were analyzed by immunoblotting with antibodies against
MLV CA (top panel) and FLAG (bottom panel). (C and D) The infectivity of mixed particles containing two different p12 mutants was tested as in
(A). Either mutant 6 (C) or mutant 13 (D) were mixed with each other mutant (shown in the key), wild type FLAG-tagged p12 (orange line) or an
L-domain mutant (grey line). As a control for mixed particle synthesis, wild type p12 was mixed with an L-domain mutant (black line). For this
sample, the percentage of wild type p12 plasmid in the transfection is plotted on the x-axis. (E) Mixed virus particles containing wild type p12
and either mutant 6, mutant 14, L16A, R66A or the double mutant LR(16, 66)AA were produced and analyzed as in (A). All panels are
representative of 3 experiments. (F) Deletions of 11 or 21 amino acids (residues D43-P53 and P37-A57 respectively) were created in p12.
Additionally, an AscI site was introduced into gag corresponding to residues 49 and 50 in p12 and an alanine cassette (of 18 or 20 amino acids)
was inserted. VLPs bearing these alterations were produced and their infectivity tested in D17 cells. The mean and range of three independent
experiments are shown.
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highlighting the importance of this region of p12. How-
ever, the infectivity of N-terminal mutants varied with
different viruses. In all cases, the infectivity of mutants 6
and 8 was less than 1% that of wild type virions as was
the infectivity of GaLV mutant N. In contrast, the infect-
ivity of mutant 5 was only reduced to 12%, 22% and 51%
that of wild type for N-MLV, B-MLV and FeLV respect-
ively, and the infectivity of mutant 7 was only reduced
to 29% and 32% that of wild type for N-MLV and B-
MLV respectively. The infectivity of FeLV mutant 7 was
less than 1% that of wild type FeLV and the infectivities
of XMRV mutants 5 and 7, although not reduced as
much as the other XMRV mutants, were less than 2%
that of wild type XMRV infectivity. The differences in
the effects of these mutations were surprising because
the sequence altered in mutant 5 is highly conserved be-
tween Mo-, N- and B-MLV, XMRV and FeLV, and the
region modified in mutant 7 is identical between Mo-,
N- and B-MLV and XMRV (Figure 3A). This suggests
that the importance of individual amino acids depends
on the context. Nevertheless, the requirement for the N-
and C-terminal domains of p12 during infection is con-
served for gammaretroviruses, although, in contrast to
the C-terminal domain, the sequence of the N-terminal
domain appears to be less sensitive to mutation.
N-terminal p12 mutants cannot saturate TRIM5alpha or
Fv1 restriction
Mutation of p12 results in inhibition of viral replication
at stages of the life cycle reminiscent of the blocks
imposed by the cellular restriction factors TRIM5alpha
and Fv1 (prior to reverse transcription and integration
respectively) [2]. The viral target for these restriction
factors is the mature CA protein [2] and it has been pro-
posed that p12 is functionally connected to CA [19].
We, therefore, wondered whether mutating p12 would
impact the ability of VLPs to saturate these restriction
factors, and by synthesizing N- and B-MLV p12 mutants
(Figure 3) we were able to test this. We added increasing
amounts of LacZ-encoding N-MLV tester virus carrying
p12 mutations or wild type N- or B-MLV controls, fol-
lowed by a fixed and equal amount of GFP-encoding
wild type N-MLV reporter virus to either TE671 cells
(Figure 4A) or B3T3 cells (Figure 4B) that express TRIM5-
alpha or Fv1b respectively. The percentage of cells expres-
sing GFP was measured three days post infection. If the
tester virus can be recognized by the restriction factor,
then adding increasing amounts of virus will saturate
the factor, allowing the second infection by the GFP
reporter virus to proceed without restriction. Thus, prior
exposure of the cells to the restricted N-MLV tester
virus enabled the N-MLV GFP reporter virus to effi-
ciently infect both TE671 and B3T3 cells (Figure 4A and
4B, black triangles) whereas prior exposure to B-MLV,
which is not restricted in these cells, had no effect on
the reporter virus infection (black squares). Figures 4A
and 4B show that in both cell types, mutants 13 and 15
were able to abrogate restriction as well as wild type N-
MLV. This indicates that although these mutants are
non-infectious, the restriction factors are able to
recognize them, in turn implying that their CA shells
are fully processed, assembled and present in an access-
ible compartment of the cell. Mutant 7 was also able to
saturate both restriction factors as well as wild type N-
MLV, although this was less surprising because this mu-
tation in N-MLV only moderately reduces infectivity
(Figure 3C and Additional file 2A). Mutant 5 was able
to partly saturate both factors (Figure 4A and 4B), which
may reflect the level of infectivity of this mutant
(Figure 3C and Additional file 2A). N-MLV mutants 6
and 8 were unable to abrogate TRIM5alpha restriction
and only had a minor effect on Fv1b restriction, suggest-
ing that the restriction factors cannot interact with
these particles (Figure 4A and 4B). Therefore, the differ-
ent mutations in p12 result in different abilities to satur-
ate retroviral restriction factors. The same trends were
seen in NIH-3T3 cells with B-MLV p12 mutants (data
not shown).
As N-MLV mutants 5 and 7 were relatively infectious,
we could not extrapolate the results to the defective
Mo-MLV mutants 5 and 7 and draw a general conclu-
sion about the abrogation ability of the N-terminal
mutants. It was possible that the failure to abrogate re-
striction was linked to the defect in reverse transcription
rather than a general N-terminus property. Unfortu-
nately, a high background prevented us from measuring
the levels of cDNA produced from either Mo-MLV or
N-MLV in TE671 or NIH-3T3 cells, but we were able to
measure the ability of N-MLV to reverse transcribe in
D17 cells (Additional file 3). All of the N-MLV mutants
appeared to reverse transcribe in these cells, including
N-MLV mutant 6, consistent with the notion that the
precise timing of the block varies with virus and cell type
and suggesting that the failure to saturate restriction fac-
tors was not due to a failure to reverse transcribe. How-
ever, to address this fully, we made mutations in the CA
region of the gag gene for each of our Mo-MLV mutants
that result in three amino acid changes in CA; D82N,
A110R and H117L, and converts Mo-MLV into an N-
tropic virus (labelled N/Mo) [23]. The conversion of
these residues did not alter the infectivity of any of the
VLPs in D17 cells (Additional file 2B). In saturation
assays, the N/Mo VLPs with wild type p12 or any of the
C-terminal changes were able to saturate TRIM5alpha in
TE671 cells nearly as well as wild type N-MLV
(Figure 4C). Conversely, the N/Mo VLPs carrying altera-
tions to the N-terminus of p12 all failed to abrogate
TRIM5alpha restriction (Figure 4C).
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There are a number of potential reasons why the N-
terminal mutants are unable to saturate TRIM5alpha.
One is that these mutations in the p12 region of gag
affect the production of functional CA protein and this
prevents the particles from being recognized. In order to
address this, we performed saturation assays in TE671
cells with mixed particles that contained a mixture of N-
and B-tropic CA in addition to mutated and wild type
Figure 3 The effects of p12 mutations in different gammaretroviruses. (A) An alignment of the p12 sequence from various gammaretroviruses
is shown. Shaded boxes indicate the position of each p12 mutant in each species and colours correspond to the bar colours in the graphs below. As
GaLV has a small N- terminal region, the mutant TDDLL/AAAAA has been named GaLV N (G). (B-G) LacZ-encoding wild type or mutant VLPs were
produced for each species of gammaretrovirus and equivalent RT-units of VLPs were used to challenge D17 cells. Infectivity was measured by
detection of β–galactosidase activity in a chemiluminescent reporter assay. Results are plotted as the percentage of infectivity compared to the
infectivity of the corresponding wild type VLPs for each species. The mean and range of three independent experiments are shown.
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p12 (Figure 4D). Particles were synthesized by mixing
Gag-Pol expression plasmids as follows: 90% N-MLV
mutant 6 with 10% wild type B-MLV (N6/B), 90% B-
MLV mutant 6 with 10% wild type N-MLV (B6/N) or
90% N-MLV mutant 6 with 10% wild type N-MLV (N6/
N). As seen in previous mixed particle experiments with
N-terminal mutants (Figure 2A), including 10% wild
type p12 in the transfection mixes ensured that all
viruses were fully infectious in D17 cells (Additional file
2C). Of the three mixed particles, N6/B, and N6/N were
able to saturate TRIM5alpha as well as wild type N-MLV
and N-MLV mutant 13, despite 90% of the CA protein
being produced from a gag gene carrying mutations in
p12 (Figure 4D, orange and dark red lines). Moreover, all
of the N-tropic CA in N6/B was produced from a
mutated gag gene, implying that this CA protein is fully
competent to interact with TRIM5alpha. In contrast, the
B6/N particles were unable to saturate TRIM5alpha as
they only contained 10% N-tropic CA and so would not
be recognized by the restriction factor. We saw the same
effect when we made similar mixed particles with N-
MLV mutant 8 and when we infected B3T3 cells with ei-
ther virus set (data not shown). Thus, it seems that
mutations in the p12 region of gag do not cause aberrant
CA function and the inability of the N-terminal mutants
to saturate restriction factors is likely attributed to the
loss of p12 function directly. This implies that the N-
terminal p12 mutants are already defective before re-
striction factor binding, ie very early in infection, and
suggests a role for p12 in core stability or localization.
Mutations in the C-terminus of p12 can be rescued by a
chromatin binding motif
Alterations to the C-terminus of p12 did not affect rec-
ognition of the viral core by restriction factors (Figure 4)
and it is apparent that the functional requirement for
the C-terminal domain is a later event in the viral life
cycle than the requirement for the N-terminus
(Figure 2E). Previous studies showed that during mitosis,
the co-localization of p12 with chromatin was greatly
reduced for a C-terminal mutant protein [20]. Moreover,
although alterations to the C-terminus inhibited integra-
tion of viral cDNA in vivo, PICs derived from at least
one mutant virus were competent to integrate in vitro
[10], suggesting that p12 may function to locate the PIC to
Figure 4 The ability of p12 mutants to saturate TRIM5alpha
and Fv1 activity. (A and B) Supernatants from 293T cells containing
LacZ-encoding N-tropic MLV (N-MLV) tester viruses, with or without p12
mutations, or B-MLV were serially diluted 2-fold and used to challenge
TE671 cells, which express TRIM5alpha (A), or B3T3 cells, that express
Fv1b (B). After 4 to 6 hours, the cells were infected a second time with a
fixed dose of GFP-encoding N-MLV reporter virus. The percentage of GFP
positive cells is plotted for each volume of tester virus. (C) Mo-MLV p12
mutants were converted to N-tropic viruses by changing 3 residues in
CA. These mutants (named N/Mo) were used as tester viruses in TE671
cells as described in (A). (D) Mixed particles that contained a mixture of
N- or B-tropic CA in addition to mutated and wild type p12 were
synthesized as follows: 90% N-MLV mutant 6 with 10% wild type B-MLV
(N6/B, orange line), 90% B-MLV mutant 6 with 10% wild type N-MLV (B6/
N, brown line) and 90% N-MLV mutant 6 with 10% wild type N-MLV
(N6/N, dark red line). These viruses were used to test abrogation of
TRIM5alpha restriction in TE671 cells as described in (A). All graphs are
representative of at least three independent experiments.
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chromatin. We therefore introduced the 14 amino acid
chromatin binding sequence (CBS) motif from prototype
foamy virus (PFV) into the inter-domain region of
Mo-MLV p12 mutants to attempt to rescue the block
to infection [24,25]. Unexpectedly, inserting the CBS
into wild type p12 reduced the infectivity of viral particles
to 10% that of wild type virions (Figure 5, red bars), raising
the possibility that the CBS changes the chromatin
targeting of Mo-MLV and that it is suboptimal. Adding
the CBS to p12 mutants 6 or 7 had no affect on the infect-
ivity of the resulting VLPs (Figure 5). However, particles
carrying either the C-terminal mutation 14 or 15 as well
as the CBS were ~100 fold more infectious than mutant
14 or 15 virions alone (Figure 5, purple and pink bars),
and were as infectious as wild type particles carrying the
CBS. This striking result indicates that the CBS can rescue
the defect seen in the C-terminal mutants, implying
that the C-terminus of p12 has a chromatin binding
function.
The C-terminus of p12 is more sensitive to single amino
acid changes than the N-terminus
To more precisely map residues that comprise the func-
tional domains at the N- and C-terminal regions of p12,
each of the residues altered in the Mo-MLV alanine sub-
stitution mutants (Figure 6A) was changed to alanine
and the infectivity of the resulting mutant particles was
tested in a single cycle assay. Figure 6B shows the
relative infectivity of the mutants to both wild type parti-
cles (set at 100%) and their “parental” alanine substitu-
tion mutant with stretches of 5–6 amino acids changed
to alanine (coloured bars). Many individual changes had
no effect on infectivity (changing residues P11, P13, S17,
S19, G20, G21, P22, I24, T28, P60, S65, G69, E72, P73,
P74) whilst, more surprisingly, some recapitulated the
parental phenotype (L16, D25, S61, P62, M63, R66, L67,
R68, R70, R71). The remaining mutations reduced in-
fectivity by approximately 2-30 fold. The effect of alter-
ing single amino acids was most striking when changes
were made at the C-terminal region of p12. Here, indi-
vidual changes either had no effect on infectivity or
reduced infectivity by >100 fold, to the levels seen with
the parental mutants. One serine and the four arginine
residues have previously been shown to be essential for
infectivity [13], however the fact that the additional resi-
dues in between are also essential suggests that the run
of amino acids from S61 to R71 may form an important
motif. The effect of individual amino acid changes at the
N-terminus of p12 was less pronounced. Several changes
resulted in reduced viral infectivity compared to wild
type virions, but not to the levels of the parental
mutants, suggesting that the combination of residues is
important. This is particularly obvious with mutant 5,
where no individual change reduced infectivity more
than 10 fold but a combination of three changes (K10,
K12, Q14) reduced infectivity to <1% that of wild type
virions (Figure 6B). Only six individual changes within
the N-terminus of Mo-MLV reduced infectivity more
than 10 fold: V15A, L16A, L23A, D25A, L26A and
L27A. Strikingly, four out of the six residues were leu-
cine. Two of these leucines (L26 and L27) together with
D25 have recently been show to be a clathrin binding
motif in p12 [21].
Comparing the sequences mutated in Mo-MLV
mutants 5–8 and 13–15 with the other gammaretro-
viruses (Figure 3A, coloured boxes) revealed seven resi-
dues that were identical between all six viruses (in Mo-
MLV numbering, D18, L23, L26, L27, E29, P62 and P74)
together with several conservative changes. Of the iden-
tical residues, only P74 was shown to be completely dis-
pensable for Mo-MLV p12 function in our alanine
scanning experiment (Figure 6B). The D18A mutation in
Mo-MLV reduced the viral infectivity to 20% that of wild
type virions, however, the D25A mutation resulted in
<1% wild type infectivity. Because the N-terminal
regions of KoRV and GaLV are so short, it is possible
that the asparagine residue(s) near the start of these
sequences should really be aligned to D25 instead of
D18 (Figure 3A). Therefore, to compare the residues in
GaLV with Mo-MLV and assess the importance of each,
we changed individual amino acids in GaLV p12 to ala-
nine (Figure 6C). Interestingly, neither the D4A nor
Figure 5 The effect of inserting a chromatin binding domain
into p12. Sequence coding for the 14 amino acid PFV chromatin
binding sequence (CBS) was inserted into the middle of p12 in Mo-MLV
Gag-Pol expression vectors carrying wild type p12 or p12 mutants 6, 7,
14 or 15 following introduction of an AscI site. These plasmids were
used to synthesize LacZ-encoding VLPs in 293T cells. D17 cells were
challenged with equal RT-units of VLPs and infectivity was measured by
detection of β–galactosidase activity in a chemiluminescent reporter
assay. Infectivity is plotted as a percentage of the infectivity of Mo-MLV
containing wild type p12 without the introduced AscI site. The mean
and range of three independent experiments are shown.
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D5A changes affected infectivity more than three fold.
Only one change in the N-terminus, L8A reduced infect-
ivity >99%. This implies that the DLL motif thought to
bind clathrin in Mo-MLV was not functional in GaLV,
but also highlights the importance of leucines in the N-
terminus of p12. Like Mo-MLV, several residues in the
C-terminus of GaLV p12 appeared essential for function.
Although not identical to Mo-MLV, a motif containing a
proline and three arginines was also identified in GaLV
p12 (Figure 6C). Taken together, it seems that the com-
bination of amino acids is important in the N-terminus
of p12 whereas individual amino acids constituting an
arginine-rich motif are essential for the function of the
C-terminus.
The C-termini of Mo-MLV and GaLV p12 are
interchangeable
To further compare the p12 proteins of Mo-MLV and
GaLV, we engineered chimeras between the two. We
replaced either the N-terminus, the C-terminus or the
whole p12 sequence in Mo-MLV Gag with that from
GaLV and vice versa (for nomenclature, see Figure 7, left
hand panels), and synthesized LacZ-encoding VLPs. Al-
though introducing all or part of GaLV p12 into Mo-
MLV had no effect on particle production (Figure 7A,
middle panel), introducing the N-terminus, and to a
lesser extent full length, Mo-MLV p12 into GaLV
reduced particle release as measured by RT activity in
the producer cell supernatant (Figure 7B, middle panel).
Figure 6 Infectivity of Mo-MLV and GaLV with single amino acid changes in p12. (A) An alignment of the residues comprising the N- and
C-terminal domains of p12 in Mo-MLV and GaLV is shown. Colour shading indicates the original Mo-MLV p12 substitution mutants synthesized.
(B and C) Single alanine substitutions were made for each residue within these domains for Mo-MLV p12 (B) or GaLV p12 (C). LacZ-encoding
mutant VLPs were synthesized and equivalent RT-units of VLPs were used to challenge D17 cells. Infectivity was measured by detection of
β–galactosidase activity in a chemiluminescent reporter assay. Results are plotted as the percentage of infectivity compared to the infectivity of
the corresponding wild type VLPs for each species. The mean and range of three independent experiments are shown.
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This is probably because the longer MLV p12 interferes
with GaLV particle assembly. However, when particle
titres were normalized, it was clear that Mo-MLV p12
could functionally replace GaLV p12 (Figure 7B, right
panel), whereas only the C-terminus of GaLV p12 was
interchangeable with Mo-MLV p12 (Figure 7A, right
panel). This is not surprising, as the N-terminus of
GaLV is very short compared to Mo-MLV, but it sug-
gests that the N-terminus of p12 may interact with a
viral factor as the combination of p12 and other viral
proteins seems to be critical. To confirm that the
chimeric Gag proteins were cleaved normally, we
performed immunoblot analysis on viral particles
(Additional file 4). Unfortunately, none of our anti-MLV
antibodies recognized GaLV Gag proteins. However, by
using a combination of our anti-MLV p12 monoclonal
and polyclonal antibodies, that recognize the N- and C-
terminus of Mo-MLV p12 respectively, we were able to
detect cleaved p12 from all the chimeras that contained
at least part of Mo-MLV p12 (Additional file 4). It did
appear that the release of p12 from the MA-p12 precur-
sor was slightly reduced for Mo-MLV/Ga-Np12 and
GaLV/Mo-Np12, and, by inference from the reduction
of free MA protein, in Mo-MLV/Ga-p12. However, the
MA/p12 cleavage was also poor for wild type Mo-MLV
(Additional file 4, Figure 1D and [8,15,21]). And as com-
pletely blocking the cleavage between MA and p12 only
moderately reduces viral infectivity (less than 10 fold)
[16], we think it is unlikely that this accounts for the in-
ability of the N-terminus of GaLV p12 to functionally re-
place the N-terminus of Mo-MLV p12 (Figure 7A, right
panel).
p12 does not self associate in vitro
Mo-MLV p12 protein was purified from E. coli using a
GST tag. The protein was soluble at pH 1.8 and when
heated at 65°C, indicating either highly reversible rena-
turation/denaturation or that it has little tertiary struc-
ture at all, at least when unbound to interaction
partners. Multi-angle laser light scattering (MALLS) and
analytical ultracentrifugation (AUC) were used to deter-
mine that p12 was a single species (Figure 8A) with a
narrow distribution of molar mass with no significant
concentration dependency (Figure 8A). In order to con-
firm the MALLS data, quantitative sedimentation equilib-
rium experiments at multiple rotor speeds and varying
sample concentration were undertaken (Figure 8B). No
concentration dependency was apparent, so global fitting,
incorporating the data from multiple speeds and multiple
sample concentrations, was applied to extract a final
weight-averaged molar mass of 9.3 ± 0.2kD (Figure 8B).
The finding that p12 remains a monomer, even at high
concentrations, is important information for constructing
a model for p12 function, as these data demonstrate that
Figure 7 Infectivity of Mo-MLV/GaLV p12 chimeras. The diagrams on the left show the design of chimeric Gag-Pol plasmids based on (A)
Mo-MLV with either the whole of p12, or just the N-terminus or C-terminus of p12 replaced with the p12 from GaLV, and (B) GaLV with either
the whole of p12, or just the N-terminus or C-terminus of p12 replaced with the p12 from Mo-MLV. These chimeric Gag-Pol plasmids were used
to produce LacZ-encoding mutant VLPs in 293T cells and RT activity was quantified by a modified ELISA as a measure of viral synthesis (middle
panels). Equivalent RT-units of VLPs were used to challenge D17 cells and infectivity was measured by detection of β–galactosidase activity in a
chemiluminescent reporter assay (right panels). Results are plotted as the percentage of infectivity compared to the infectivity of the
corresponding wild type VLPs for each species. The mean and range of three independent experiments are shown.
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the dominant negative phenotype of the C-terminal
mutants is unlikely to result from p12 self-association.
Discussion
The early post-entry stages of the retroviral life cycle are
targets for several restriction factors and antiretroviral
drugs [2,26]. However, many of these steps, such as
uncoating, trafficking and nuclear localization are poorly
defined. A better understanding of the processes and
interactions that occur during early infection may lead
to novel therapeutics for retroviral infections and
improved retroviral vector design. In 1999, Yuan et al.
showed that the p12 protein of MLV was essential dur-
ing the early stages of MLV replication [8] and a later
study identified “footprints” in p12 where insertions
inhibited viral infectivity [9]. However, the function of
p12 has remained obscure. Further studies showed no
gross differences in PIC structure between wild type and
mutant virions [10], and the mutant PICs tested were
competent to integrate in vitro [10]. Although the pro-
tein appears to be phosphorylated in cells, this does not
seem to be necessary for function [13].
To enable us to perform a variety of assays and infect
multiple cell lines, we cloned the panel of p12 mutants
synthesized by Yuan et al. into a Mo-MLV Gag-Pol vec-
tor and showed that the infectivity of the resulting VLPs
was reduced to near background levels in a range of dif-
ferent cell lines (Figure 1C and Additional file 1). Par-
ticle production was only reduced for mutant 8 and Gag
processing was normal for all mutants (Figure 1B and
1D). This implies that p12 function is independent of
the viral envelope, route of entry and the viral gene-
encoding RNA and it is not species specific, suggesting a
more fundamental role during infection. Interestingly,
particles with modifications to the N-terminus of p12
had different phenotypes to particles with alterations in
the C-terminus of p12 (Figure 2A), suggesting that these
regions formed separate “domains” with distinct func-
tions. The length and composition of the linker between
these domains could be modified without affecting viral
infectivity (Figure 2F), but both domains had to be
present on the same molecule to function (Figure 2C
and 2D).
The dominant negative phenotype of the C-terminal
mutants and the N-terminal-like phenotype of the
double mutant in our mixed particle assays (Figure 2A
and 2E), suggests that p12 makes important interactions
at the N-terminus that are still able to occur when the
C-terminus is defective, such that C-terminally modified
p12 molecules compete with wild type p12 proteins.
This implies that the N-terminus of p12 likely makes
interactions before the C-terminus is required and/or
binds a limiting factor. As we have shown that p12 does
not self-associate in vitro at high concentrations
Figure 8 Biophysical analysis of purified p12 protein. A)
SEC-MALLS analysis of p12. Scattered light intensity (solid line) and
differential refractive index (dashed line) are plotted against
retention time. Traces from p12 samples applied to a G75 (10/30)
size exclusion column at 9.0 mg/ml (blue) and 4.5 mg/ml (red) are
shown. The molar mass distributions, plotted as points, were
determined throughout each peak as described in the text. B)
Sedimentation equilibrium analysis of p12. A typical multispeed
sedimentation equilibrium profile obtained from interference data
collected on p12 at 100 μM is shown. The data were collected at 20,
25 and 30 krpm (red, green and blue points respectively). A global
fit single-species ideal solution model incorporating data from all
speeds and concentrations (black lines) gives a p12 molar mass of
9.3kD.
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(Figure 8), although with the caveat that the concentra-
tion of p12 in viral particles is possibly greater than in
our experiments, we propose that p12 links two other
factors together. It has been shown that p12 co-localizes
with nascent viral cDNA and CA proteins in the viral
PIC [20]. We hypothesize that p12 links the viral PIC to
cellular chromatin. In this scenario, first the N-terminus
of p12 would bind the PIC (the limiting factor) and then
the C-terminus would bind chromatin once the nuclear
envelope has broken down during mitosis, tethering the
PIC to cellular DNA, ready for integration (Figure 9).
By inserting the CBS from PFV [24,25] into p12
(Figure 5), we have shown that the defect imposed by
changes to the C-terminus of p12 can be overcome by
providing an alternative route for chromosome binding,
although the CBS presumably doesn’t recapitulate the
normal process of chromosome binding as adding this
motif to wild type p12 reduces infectivity by approxi-
mately 90%. This could also explain why PICs from vir-
ions with defects in the C-terminus of p12 are
competent to integrate into naked DNA in vitro, where
locating and tethering target DNA is unlikely to be as
complex [10]. Moreover, C-terminally defective PICs did
not co-localize with mitotic chromatin in microscopic
studies [20]. A chromatin-binding role for the C-
terminus of p12 would also fit with the fact that its func-
tion seems to be conserved in other gammaretroviruses
(Figure 3) and especially with our findings that the C-
terminus of GaLV and MLV are functionally
exchangeable (Figure 7). Our data, that even single
amino acid changes in the C-terminus of p12 completely
ablate function in both viruses (Figure 6), imply that the
C-terminus harbors a binding motif. Although the
amino acid sequence is not perfectly conserved across
gammaretroviruses, the requirement for a cluster of argi-
nines appears constant (Figure 3A). It is tempting to
speculate that p12 may provide the function for gam-
maretroviruses that LEDGF provides for HIV [11,12], es-
pecially when it was reported over 30 years ago that p12
has sequence homology with histone H5 [27], albeit at
the N-terminus, but further work is required to deter-
mine whether the interaction with chromatin is direct or
occurs via an intermediate factor.
The function of the N-terminus of p12 appears to be
more complex. Although changing 5–6 amino acids to
alanine within a 21 amino acid stretch is detrimental to
Mo-MLV, not all of these changes inhibit function in
other gammaretroviruses (Figure 3). In particular, the
residues altered in mutant 7 are identical between Mo-
MLV and N-MLV and yet mutating them in Mo-MLV
leads to ~99% reduction in infectivity (Figure 3B, dark
blue bar) whilst the same mutation in N-MLV only
reduces infectivity three fold (Figure 3C, dark blue bar).
Therefore, the context of the amino acids seems to be
important. We propose that the N-terminus of p12
binds to a viral component of the PIC, accounting for
the different requirement for particular residues in p12
depending on what the specific binding target is. The
Figure 9 Model for the function of p12 during the early stages of retroviral replication. In addition to the late-domain, we propose that
p12 carries two early domains in the N-terminus (Early-A, E-A, green box) and the C-terminus (Early-B, E-B, purple box). (A) Infection of a cell with
a gammaretrovirus containing wild type p12 leads to successful integration of viral cDNA (turquoise) into the host chromatin. (B) Alterations to
the N-terminal domain of p12, E-A, affect the stability of the viral core and abort infection very early in the replication pathway, sometimes
inhibiting reverse transcription. The virus is therefore unable to abrogate restriction factors. (C) Alterations to the C-terminal domain of p12, E-B,
do not affect the very early stages of infection and p12 is present in the PIC by virtue of interactions at the N-terminus. However, p12 is unable
to tether the PIC to host chromatin and the viral cDNA cannot integrate successfully into the DNA of the host.
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specificity of the interaction may also explain why the
N-terminus of Mo-MLV p12 can replace the function of
the N-terminus of p12 in GaLV (Figure 7B), but the
GaLV p12 cannot replace that of Mo-MLV (Figure 7A).
Moreover, for most of the residues in the N-terminus of
both Mo-MLV and GaLV, single alanine substitutions
had little effect on viral infectivity (Figure 6). For ex-
ample, the K10A, K12A and Q14A changes in Mo-MLV
individually reduce infectivity <90%. However, making
all three changes together reduces infectivity >99.5%.
This leads us to hypothesize that the N-terminus of p12
makes multiple weak interactions that act in concert to
form a strong interaction, perhaps binding a large sur-
face. The CA shell of the viral core would be a possible
example of such a surface and it has been proposed that
the restriction factors Fv1 and TRIM5alpha bind this
surface through multiple weak interactions [28].
Based on the results of the restriction factor saturation
assays (Figure 4) it is clear that mutations in the N-
terminus of p12 affect the ability of the restriction factors
to recognize the CA shell. One way this could happen is
if p12 binding normally stabilizes the CA shell. Altera-
tions to p12 could prevent this stabilization, causing the
core to breakdown prematurely before restriction factor
binding. Alternatively, mutant p12 could still bind to the
core but somehow prevent access by the restriction fac-
tor, although it is not clear how this would inhibit viral
infectivity. Finally, mutations in p12 could alter the
localization of the viral core in the cell, taking it to a lo-
cation not accessible to restriction factors, nor conducive
to a productive infection. Such compartmentalization has
not been reported for retroviruses or restriction factors.
Thus, our favored theory is that p12 helps to stabilize the
viral core, perhaps even regulating the uncoating process.
It has been suggested that uncoating is linked to reverse
transcription [29] so, if the different mutants have differ-
ent effects on the kinetics of uncoating, this may also
affect the ability of the virus to reverse transcribe. This
could explain how some N-terminal p12 variants affect
reverse transcription in cells (Figure 1E), without affect-
ing RT activity in an exogenous setting (Figure 1B). The
precise timings of these events may be cell-specific,
accounting for why the timing of the block varies for mu-
tant 8 (Figure 1E, dark green line and [8]). However,
TRIM5alpha is thought to bind to the core very early
after membrane fusion before reverse transcription [30]
so if particles carrying N-terminal p12 changes are
already defective at this early stage, it is notable that
reverse transcription takes place in most cases. Indeed,
further studies on p12 may help elucidate the relationship
between reverse transcription and uncoating.
It is not clear whether binding the CA shell would be
sufficient to couple p12 to the PIC or whether the N-
terminus of p12 would need to make additional
interactions in order to perform its chromosomal tether-
ing function. It has been shown that the DLL motif in
the N-terminus interacts with clathrin [21], although the
significance of this interaction remains unknown. The
authors claimed that mutating this motif led to defects
in p12 processing. However, we have shown that this
may be an artefact of using particular antibodies for
their study and clearly show that the p12 in mutant 8, in
which the DLL motif is changed to AAA, is fully pro-
cessed and incorporated normally into particles
(Figure 1D). As the DLL motif is present in the other
p12 mutants, this cannot account for the loss of function
of most of the mutants.
Finally, the mixed particle experiments (Figure 2) sug-
gest that only a fraction of the p12 in a viral particle is
required to have a functional N-terminus, and therefore,
by extrapolation from the fact that both domains must
function on the same molecule (Figure 2C and 2D), only
a small amount of active p12 is required for function. It
seems reasonable that a limited amount of p12 would
bind to a PIC (that contains only a subset of viral pro-
teins and a single double stranded DNA) in order to
tether it to chromatin, but further work is required to
show how such a small amount of p12 could stabilize
the CA shell. It is somewhat surprising that the cleavage
of MA and p12 appears to be inefficient in wild type vir-
ions (Figure 1D and [8,15,21]). Indeed, this may be
explained by the requirement for only a small amount of
p12. Moreover, mutations that result in inhibiting this
cleavage event only moderately affect viral infectivity
[16], suggesting that p12 may retain much of its function
even when fused to MA. In this scenario, a small
amount of MA may be associated with the PIC.
Conclusions
Prior to our study, the function of p12 during the early
stages of MLV replication was unknown. Although there
are undoubtedly other possible explanations for some of
our results, we would like to propose a model for p12
function as shown in Figure 9: After Gag processing, the
N-terminus of a proportion of the p12 protein in the
particle interacts with the CA shell surrounding the viral
core to regulate the uncoating process and allow reverse
transcription to proceed. The p12 protein remains asso-
ciated with the PIC as it traffics to the nucleus of the
cell. As the cell enters mitosis and the nuclear envelope
breaks down, the C-terminus of p12 interacts with cellu-
lar chromatin, targeting the PIC to the appropriate loca-
tion for integration to occur and ensuring that the viral
DNA is retained in the nucleus as the nuclear mem-
brane reforms.
We hope that it will now be possible to test this hy-
pothesis further and finally confirm the function(s) of
the last remaining MLV Gag protein to be characterized.
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Methods
Plasmids and cloning
To synthesize VLPs, three plasmids were co-transfected
into 293T cells: An envelope expression construct for
the vesicular stomatitis virus G protein (pczVSV-G) [31],
a Mo-MLV-based retroviral vector encoding LacZ
(pczLTR-LacZ) [32] or eGFP (pLNCG) [31,33] and a
Gag-Pol expression plasmid. Wild type Mo-MLV Gag-
Pol (named Mo-MLV) was expressed from pKB4, a vec-
tor synthesized by cloning the gag-pol region from
pMD-MLV Gag-Pol [32] into pcDNA3.1, described pre-
viously [34]. N- and B-tropic MLV Gag-Pol expression
vectors (pCI G3N and pCI G3B) have been described
[31]. HG1 is a replication-incompetent XMRV clone in
the pcDNA3.1 mammalian expression vector and has
been described previously [34,35]. A stop codon was
introduced into the env sequence at nucleotide 76–78
by site directed mutagenesis using primers: for
5’-gataattatggggatctaggtgagggcaggagcct and rev 5’-
aggctcctgccctcacctagatccccataattatc to make the plasmid
HG1-env. To produce a FeLV Gag-Pol expression plas-
mid, the FeLV gag-pol sequence from pczFeLVgp (a gift
from J. Stoye) was cloned into pcDNA3.1 using the NheI
and NotI restriction enzymes, and named pDJW1. GaLV
Gag-Pol was expressed from a pcDNA3.1-based vector,
pczGaLVgp (a gift from J. Stoye).
All Mo-MLV 5–6 amino acid alanine substitution
mutants were generated by replacing the BsrGI-XhoI frag-
ment from pKB4 with the corresponding mutated p12
fragments from proviral p12 mutants pNCS-PM5, -PM6,
-PM7, -PM8, -PM13, -PM14, -PM15, -FLAG and –L do-
main (gifts from S. Goff [8]) creating a pKB series of
mutants (pKB5, 6, 7, 8, 13, 14 and 15). Similar alanine
substitution mutations were introduced into the p12
regions of N-tropic MLV, B-tropic MLV, XMRV, FeLV and
GaLV by site directed mutagenesis of pCI G3N, pCI G3B,
HG1-env, pDJW1 and pczGaLVgp respectively using the
QuikChange kit (Stratagene). The primer sequences for
each mutant are given in Additional file 5. Single amino
acid changes were also introduced into Mo-MLV and
GaLV by site directed mutagenesis of pKB4 and
pczGaLVgp. The primer sequences for each mutant are
given in Additional file 6. Additionally, deletions in p12
were generated by site directed mutagenesis of pKB4.
Residues D43-P53 in p12 were removed using primers:
for 5’-ccacccccttccgcgggagaggca and rev 5’-tgcctctcccgcg
gaagggggtgg, and residues P37-A57 were removed using
primers: for 5’-gccttatagggacccggacccctccc and rev 5’-
gggaggggtccgggtccctataaggc. To make insertions in p12, a
unique AscI restriction site was first introduced into the
p12 sequence in pKB4, pKB6, pKB7, pKB14 or pKB15 by
site directed mutagenesis, generating pKB-AscI vectors.
The mutations t144c, g146c, a147g, g148c and a149c were
synthesized using primers: for 5’-cgacagggacggaaatggcgc
gccagcgacccctgcgggag and rev 5'-ctcccgcaggggtcgctggcg
cgccatttccgtccctgtcg. Linkers encoding the sequence to be
inserted flanked by AscI sites were prepared by heating 4
μM complimentary oligonucleotides at 95°C for 5 minutes
followed by annealing at 65°C for 10 minutes on a thermal
cycler (Biorad). The annealed oligonucleotides were then
cloned into the AscI site in the pKB-AscI vectors resulting
in insertions between p12 residues 49 and 50 of: PA15GA
(ins 18), PA17GA (ins 20) or the 14 amino acid CBS motif
with a linker (P <NQGGYNLRPRTYQP>AG).
To convert wild type and p12 mutant Mo-MLV VLPs
into N-tropic particles, mutations coding for three
amino acid changes in CA; D82N, A110R and H117L,
were introduced into the CA region of the appropriate
wild type or mutant Mo-MLV Gag-Pol expression plas-
mid. These changes have previously been shown to make
Mo-MLV particles sensitive to Fv1b [23]. The changes
were made by site directed mutagenesis using the Quik-
Change kit (Stratagene) with the following primers:
D82N for 5’-gcggtgcggggcaatgatgggcgcccc, D82N rev
5’-gggcgcccatcattgccccgcaccgc, A110R for 5’-gggattacac
cacccagcgaggtaggaaccacctagt, A110R rev 5’-actaggtggt
tcctacctcgctgggtggtgtaatccc, H117L for 5’- ggtaggaac
cacctagtcttgtatcgccagttgctcctagc, H117L rev 5’- gctagga
gcaactggcgatacaagactaggtggttcctacc.
Chimeric p12 sequences were constructed by overlap-
ping PCR from three DNA fragments amplified from ei-
ther pKB4 (for Mo-MLV sequence) or pczGaLVgp (for
GaLV sequence). All DNA fragments were amplified
using Phusion DNA polymerase (Finnzymes) according
to the manufacturer’s instructions. The amino acid se-
quence at the crossover junctions in the Mo-MLV based
chimeras are as follows (i) Mo-MLV/Ga-p12: Mo-MLV
MA(.. SSLY/PALTDD..) GaLV p12 and GaLV p12(..
DSTVIL/PLRA..) MoMLV CA; (ii) Mo-MLV/Ga-Np12:
Mo-MLV MA(.. SSLY/PALTDD..) GaLV p12 and GaLV
p12(.. LLSEPT/PPPY..) MoMLV p12; (iii) Mo-MLV/Ga-
Cp12: Mo-MLV p12(.. PPPY/PAALPP..) GaLV p12 and
GaLV-p12(.. DSTVIL/PLRA..)Mo-MLV CA. The final
PCR fragments were amplified with primers for 5'-
ccgcatggacacccagacca, and rev 5'-tggggcttctgcccgcgttt,
and inserted into pKB4 between the BsrGI and XhoI
sites. The amino acid sequences at the crossover junc-
tions in the GaLV based chimeras are as follows: (i)
GaLV/Mo-p12: GaLV MA(.. PPIY/PALTPS..)Mo-MLV
p12 and Mo-MLV p12-(.. TTSQAF/PLRA..) GaLV CA;
(ii) GaLV/Mo-Np12: GaLV MA(.. PPIY/PALTPS..)Mo-
MLV p12 and Mo-MLV p12(.. EDPPPY/PAAL..) GaLV
p12; (iii) GaLV/Mo-Cp12: GaLV p12(.. SEPT/PPPYRD..)
MoMLV p12 and Mo-MLV p12(.. TTSQAF/PLRA..)
GaLV CA. Due to the lack of suitable restriction sites in
pczGaLVgp, a BsrGI site was introduced into this plas-
mid 5' of gag, and an XhoI site 3' of pol was removed,
both by site directed mutagenesis. The final chimeric
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fragments were amplified using primers, for 5'-gcagatatc-
cagcacagtgg, and rev 5'-cagaagacgctccctacctg, and
inserted into pczGaLVgp between the introduced BsrGI
site and a now unique XhoI site. The BsrGI site was then
removed by site directed mutagenesis.
Cells
All cell lines (293T, HeLa, TE671, Vero, MDBK, PK15,
CF2TH, D17, MDCK, CRFK, CHO, CV-1, AH927, SIRC,
B3T3, M. dunni and NIH-3T3) were maintained in
DMEM (Invitrogen) supplemented with 10% heat inacti-
vated foetal calf serum (Biosera) and 1% penicillin/
streptomycin (Sigma), in a humidified incubator at 37°C
and 5% CO2.
VLP production
Virus-like particles of Mo-MLV, N-MLV, B-MLV, XMRV,
FeLV and GaLV were prepared by co-transfection of
293T cells with a 1:1:1 ratio (or 2:1:1 for FeLV and 3:1:1
for GaLV) of three plasmids encoding the appropriate
wild type or mutant Gag-Pol protein, VSV-G, and a re-
porter gene (β-galactosidase or GFP) respectively, using
polyethylenimine (PEI, PolySciences) as a transfection
reagent. To make mixed viral particles, wild type and
mutant Gag-Pol expression plasmids (or two different
mutants) were added to the transfection mix at different
ratios, keeping the total concentration of Gag-Pol plas-
mid constant. After ~24 hours, cells were washed and
fresh media was added for a further ~15 hours. Virus-
containing supernatants were harvested, filtered, and
viral titres were quantified using a modified ELISA for
reverse transcriptase activity (Cavidi). In the restriction
factor saturation assays, Turbofect (Fermentas) was used
as transfection reagent. Approximately 18 hours after
transfection, cells were washed and sodium butyrate
media (0.02 M sodium butyrate, 10% FCS and 1% peni-
cillin/streptomycin in DMEM) was added for 6 hours
before replacing with fresh media. VLPs were harvested
after 15 hours, as above.
Infections
VLP infectivity was determined by challenging cells at
~40% confluency (D17 cells unless stated otherwise)
with equivalent RT-units of VLPs. After 48–72 hours,
cells were lysed and β-galactosidase activity in cell
lysates was measured using the Galacto-Star system (Ap-
plied Biosystems).
For quantitative PCR analysis of viral cDNA, target
cells were plated in 6-well plates, at a density of ~4x105
cells per well, 1 day prior to infection. Equal RT-units of
VLPs were treated with RQ1-DNase (Promega) for 1
hour at 37°C to remove any contaminating DNA from
the virus preparation and then added to cells at 4°C.
Cells were incubated for 2 hours on a shaker at 4°C,
washed, resuspended in fresh DMEM and incubated at
37°C for a further 0–24 hours or 2 weeks. Total DNA
was purified using the DNeasy Blood and Tissue kit
(Qiagen) and analyzed by real-time quantitative PCR.
Restriction factor saturation assays
TE671 cells expressing endogenous TRIM5alpha or
B3T3 cells expressing endogenous Fv1b were seeded at
105 cells per well in a 12-well plate one day prior to in-
fection. Cells were infected with 2 fold serial dilutions of
freshly harvested 293T cell supernatants containing
LacZ-encoding VLPs. Cultures were incubated for 4–6
hours at 37°C before adding a fixed amount of GFP-
encoding N-MLV (equivalent to an MOI of 1 in M.
dunni cells, resulting in ~30% GFP-positive M. dunni
cells). After 72 hours, infected cells were harvested and
the percentage of GFP-positive cells was determined by
flow cytometry using a FACS Calibur analyzer (Becton
Dickinson). For each experiment, LacZ-encoding B-
tropic MLV was included as a negative control.
Quantitative PCR analysis
Minus strand strong stop reverse transcription products
were detected by amplification of the R-U3 region of
Mo-MLV corresponding to nucleotides 997–1126 of
the LacZ-LTR plasmid using primers oJWB45 (5’-
GCGCCAGTCCTCCGATAGACTGA) and oJWB47
(5’-CTGACGGGTAGTCAATCACTCAG) with probe
oJWB38 (5’-FAM-ATCCGACTCGTGGTCTCGCTGTTC-
TAMRA) [36]. Second strand extension reverse transcrip-
tion products were detected by amplification of the R-gag
region corresponding to nucleotides 997–1240 of the
LacZ-LTR plasmid using same forward primer, oJWB45,
and probe oJWB38 but with the reverse primer oJWB48
(5’- ACAATCGGACAGACACAGATAAGTTG). Reac-
tions were performed in triplicate, in TaqMan Gene Ex-
pression Master Mix (Applied Biosystems) using 900nM
of each primer and 250nM of probe. Quantitative real
time PCR was performed on a Fast 7500 PCR system
(Applied Biosystems) using standard cycling conditions
of 50°C for 2 minutes, 95°C for 10 minutes followed by
40 cycles of 95°C for 15 seconds and 60°C for 1 minute.
The LacZ-LTR plasmid was diluted into purified DNA
from the target cell line to create a series of samples that
were used to calculate relative cDNA copy numbers and
confirm the linearity of the assay.
Immunoblot analysis
VLPs were concentrated by centrifugation through a
20% (w/v) sucrose cushion for 2–4 hours at 32,000 rpm
at 4°C before immunoblot analysis. Viral CA and p12
proteins were detected using primary antibodies; rat
anti-p30CA monoclonal antibody (hybrodoma CRL-1912,
ATCC), mouse anti-p12 monoclonal (hybrodoma CRL-
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1890, ATCC), goat anti-p12 polyclonal (a gift from J.
Stoye), rabbit anti-FLAG polyclonal (sigma-aldrich) and
secondary IRDye800CW conjugated antibodies (LI-COR
Bioscience). Bands were visualized using the Li-cor
Odyssey imaging and quantitation system (LI-COR Bio-
science). MA was detected with rabbit anti-p15MA pri-
mary antibody (a gift from A. Rein) and an anti-rabbit
HRP conjugated secondary antibody using the Immobi-
lon chemiluminescent substrate (Millipore) and hyper-
film processed with a Fijifilm FPM-3800A developer.
GST-p12 protein purification
The p12 coding sequence was amplified from KB4 by
PCR using primers: DA3f, 5’-AAGGATCCCCAGCCCT
CACTCC, and KB131, 5’-CTACTCGAGTCAGAATGC
CTGCGAGGTAGTG, and inserted into pGEX6.1
between the BamHI and XhoI sites to produce an N-
terminally GST-tagged p12. The protein was expressed
in E. coli BL21(DE3) by the addition of 1 mM isopropyl-
β-D-thiogalactopyranoside (IPTG) to a mid-log culture.
Cells were harvested and resuspended in 20 mM Tris
pH7.7, 150 mM NaCl, 1 ml DTT (Buffer A) with
addition of protease inhibitors and lysed by sonication.
Clarified crude cell extracts were applied to a 5 ml GST-
trap column (GE Healthcare). After washing with Buffer
A, untagged p12 was eluted from the resin by digestion
with precision protease over night. The eluate was then
heated at 65°C for 5 minutes, centrifuged to remove pre-
cipitate and applied to a Superdex 75 (16/60) size exclu-
sion column equilibrated in Buffer A. After size
exclusion chromatography, fractions containing p12
were concentrated by ultrafiltration using Vivaspin cen-
trifugal concentrators to ~10 mg/ml and stored frozen
at −20°C. The purity of preparations was monitored by
electrospray ionization mass spectroscopy and sodium
dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE). Protein concentration was determined
from the absorbance at 280 nm.
SEC-MALLS
SEC-MALLS was used to determine the molar mass of
p12. Typically, 100 μl protein samples were applied to a
Superdex 75 10/300 GL column equilibrated in 20 mM
Tris–HCl, 150 mM NaCl and 0.5 mM TCEP, pH 8.0, at
a flow rate of 0.5 ml/min. The scattered light intensity
and protein concentration of the column eluate were
recorded using a DAWN-HELEOS laser photometer and
an OPTILAB-rEX differential refractometer (dRI) (dn/
dc= 0.186) respectively. The weight-averaged molecular
mass of material contained in chromatographic peaks
was determined from the combined data from both
detectors using the ASTRA software version 5.1 (Wyatt
Technology Corp., Santa Barbara, CA).
Analytical ultracentrifugation
Sedimentation equilibrium experiments were performed
in Beckman Optima XLI analytical ultracentrifuge using
charcoal filled epon six-channel centrepieces in an An-
50 Ti rotor. Prior to centrifugation, samples were dia-
lyzed exhaustively against the buffer blank, 20 mM
Tris–HCl, pH 7.5, 150 mM NaCl, 0.5 mM TCEP. After
centrifugation for 18 h, interference data were collected
at 2 hour intervals for 6 hours to ensure no further
change in the profiles was observed. The rotor speed
was then increased and the procedure repeated. Data
were collected on samples of 50–200 μM of p12 at 20,
25 and 30krpm. The program SEDPHAT [37] was used
to determine weight-averaged molar masses by non-
linear fitting of individual multi-speed equilibrium pro-
files to a single-species ideal solution model.
Additional files
Additional file 1: Activity of p12 mutants in a panel of cell lines.
Wild type Mo-MLV or p12 mutants 5, 6, 8 and 13 VLPs were produced in
293T cells by transient transfection and virus production was quantified
by RT-ELISA. Equivalent RT-units of VLPs were used to challenge a panel
of cell lines from different species and productive infection was
measured after 48 hours by detection of β–galactosidase activity in a
chemiluminescent reporter assay. Infectivity is reported as counts per
second and the mean and range of three independent experiments are
shown.
Additional file 2: Infectivity of particles used in TRIM5alpha and
Fv1 saturation assays (Figure 4). (A) LacZ-encoding N-MLV tester
viruses, with or without p12 mutations, or B-MLV were synthesized in
293T cells and used in TRIM5alpha and Fv1b abrogation assays (Figure 4A
and 4B). Equal RT-units of VLPs were used to challenge D17, TE671 and
B3T3 cells and infectivity was measured by detection of β–galactosidase
activity in a chemiluminescent reporter assay. Infectivity is plotted as a
percentage of the B-MLV control. (B) The infectivity of N/Mo LacZ tester
viruses that were used for TRIM5alpha abrogation assays (Figure 4C) was
tested in D17 and TE671 cells as in (A). Infectivity is plotted as the
percentage of the Mo-MLV control. (C) The infectivities of the mixed
particles N6/B, B6/N and N6/N and the control viruses that were used for
TRIM5alpha abrogation assays (Figure 4D) were tested in D17 and TE671
cells as in (A).
Additional file 3: Quantification of viral cDNA levels in D17 cells.
Wild type and mutant N-MLV VLPs were produced in 293T cells by
transient transfection and equal RT-units of VLPs were used to challenge
D17 cells. Total DNA was isolated at various times post infection as
indicated, and the relative amounts of second strand extension were
measured using qPCR. Results are representative of three independent
experiments.
Additional file 4: Immunoblot analysis of Mo-MLV/GaLV chimeras.
LacZ-encoding Mo-MLV/GaLV p12 chimeric VLPs (A) and GaLV/Mo-MLV
p12 chimeric VLPs (B) were produced by transfection of 293T cells (as in
Figure 7). Equal RT-units of particles were concentrated through 20% (w/v)
sucrose cushions and lysed in SDS loading dye. Viral proteins were separated
on a 10% polyacrylamide gel by SDS-PAGE and p12 was detected with an
anti-MLV p12 polyclonal antibody (A and B, top panels) and an anti-MLV p12
monoclonal antibody (A, middle panel; B, bottom panel). The approximate
sizes of p12 and MA-p12 are indicated. GaLV p12 is not detected with either
of these antibodies. In addition, the Mo-MLV based chimeras were probed
with anti-MLV CA and anti-MLV MA antibodies (A, bottom panels). These
antibodies did not cross react with GaLV Gag proteins.
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Additional file 5: Site directed mutagenesis primer sequences used
to construct different gammaretroviral p12 alanine substitution
mutations.
Additional file 6: Site directed mutagenesis primer sequences used
to construct single amino acid changes in p12.
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